farmacología
farmacología cardiovascular 57 | xxxxx de 2023 • 6. Light PE. Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure. Eur Heart J 2021;42:3739-40. • 7. Jhund PS, Ponikowski P, Docherty KF, et al. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation 2021;143:1962-72. • 8. Shen L, Kristensen SL, Bengtsson O, et al. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. JACC Heart Fail 2021;9:254-64. • 9. Zannad F, Rossignol P. Mineralocorticoid Receptor Antagonists and SGLT2 Inhibitor Therapy: The Best of Both Worlds in HFrEF. JACC Heart Fail 2021;9:265-7. • 10. Docherty KF, Jhund PS, Anand I, et al. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Circulation 2020;142:1623-32. • 11. Solomon SD, Jhund PS, Claggett BL, et al. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA- HF Trial. JACC Heart Fail 2020;8:811-8. • 12. Ahmad T, Desai NR. Quadruple Therapy Is the New Standard of Care for HFrEF. JACC Heart Fail 2020;8:819-21. • 13. Jackson AM, Dewan P, Anand IS, et al. Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation 2020;142:1040-54. • 14. Docherty KF, Jhund PS, Inzucchi SE, et al. Effects of Dapagliflozin in DAPA-HF According to Background Heart Failure Therapy. Eur Heart J 2020;41:2379-92. • 15. Martinez FA, Serenelli M, Nicolau JC, et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Circulation 2020;141:100-11. • 16. Kosiborod MN, Jhund P, Docherty KF, et al. Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial. Circulation 2020;141:90-9. • 17. Fang JC. Heart-Failure Therapy — New Drugs but Old Habits? N Engl J Med 2019;381:2032-42. • 18. Docherty KF, Simpson J, Jhund PS, et al. Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF. JACC Heart Fail 2022;10:104-18. • 19. Berg DD, Docherty KF, Sattar N, et al. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation 2022;145:158-69. • 20. Packer M, Anker SD, Butler J, et al., on behalf of the EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes With Empagliflozin in Heart Failure. N Engl J Med 2020;383:1413-24. • 21. Doehner W, Anker SD, Butler J, et al. Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J 2022;Jul 5:[Epub ahead of print]. • 22. Ferreira JP, Zannad F, Butler J, et al. Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled. Eur Heart J 2022;43:2984-93. • 23. Editorial: Verma S, Dhingra NK, Pandey AK, Cosentino F. Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalemia in heart failure. Eur Heart J 2022;43:2994-6. • 24. Packer M, Butler J, Zannad F, et al. Empagliflozin and Major Renal Outcomes in Heart Failure. N Engl J Med 2021;385:1531-3. • 25. Lam CS, Ferreira JP, Pfarr E, et al. Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J 2021;42:4442-51. • 26. Butler J, Anker SD, Filippatos G, et al. Empagliflozin and Health-Related Quality of Life Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: The EMPEROR-Reduced trial. Eur Heart J 2021;42:1203-12. • 27. Spertus JA. Quality of Life in EMPEROR-Reduced: Emphasizing What Is Important to Patients While Identifying Strategies to Support More Patient-Centered Care. Eur Heart J 2021;42:1213-15. • 28. Packer M, Anker SD, Butler J, et al., on behalf of the EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. J Am Coll Cardiol 2021;77:1381-92. • 29. Kosiborod MN, Vaduganathan M. SGLT-2 Inhibitors in Heart Failure: Volume or Value? J Am Coll Cardiol 2021;77:1393-6. • 30. Ferreira JP, Zannad F, Pocock SJ, et al. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPE- ROR-Reduced. J Am Coll Cardiol 2021;77:1397-407. • 31. Greene SJ, Khan MS. Quadruple Medical Therapy for Heart Failure: Medications Working Together to Provide the Best Care. J Am Coll Cardiol 2021;77:1408-11. • 32. Packer M, Anker SD, Butler J, et al., on behalf of the EMPEROR-Reduced Trial Committees and Investigators. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation 2021;143:326-36. • 33. Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-829. doi:10.1016/S0140-6736(20)31824-9. • 34. McDonagh TA, Metra M, Adamo M, Gardner RS. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; [published online August 26, 2021]. doi:10.1093/eurheartj/ehab368 • 35. Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Card Fail. 2022;28(5):e1-e167. doi:10.1016/j.cardfail.2022.02.010. EDITORIAL SCIENS // 9
